ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative and high-quality therapeutics. The company's mission is to "Serve Patients, Improve Lives" by addressing unmet medical needs. Its corporate headquarters is located in Baudette, Minnesota, with a commercial headquarters in Princeton, New Jersey.

ANI Pharmaceuticals operates through three primary business segments: Rare Disease, Generics, and Established Brands. The Rare Disease business focuses on marketing novel products across therapeutic areas such as ophthalmology, rheumatology, nephrology, neurology, and pulmonology. The Generics business leverages research and development expertise and U.S.-based manufacturing to offer a broad portfolio of generic medications. Key products include Purified Cortrophin Gel, ILUVIEN, and YUTIQ, alongside a wide variety of generic pharmaceuticals. The company also provides contract development and manufacturing services.

Recent notable developments for ANI Pharmaceuticals include the FDA approval and launch of Pimozide Tablets with 180-day CGT exclusivity and the launch of Carbamazepine Extended-Release Capsules in April 2026, expanding its generic portfolio. The company reported record fourth-quarter and full-year 2025 financial results in February 2026, reaffirming its 2026 financial guidance. Nikhil Lalwani serves as the CEO, and Thomas J. Haughey was elected Chairman of the Board in December 2025. ANI Pharmaceuticals is strategically focused on expanding its Rare Disease business and transforming into a leading company in this segment.